ARTICLE | Company News

Anaeropharma Science, Eisai deal

October 11, 2010 7:00 AM UTC

Eisai received an option to license rights to Anaeropharma's APS001. Eisai received the right of first review of the Phase I results for the recombinant Bifidobacterium longum bacteria that has been modified to expresses the cytosine deaminase gene. ASP001 is in preclinical development to treat solid tumors, with an IND submission planned for next year. ...